Ascentage Pharma Group International vs Kura Oncology
Ascentage Pharma Group International is the larger business, with $79.9m of revenue in fiscal 2025 against $67.5m for Kura Oncology (1.2 times as much). Kura Oncology grew faster (25.2% against -41.4%). Ascentage Pharma Group International kept more of each dollar of sales as profit: a net margin of -216.5% against -412.9%. Kura Oncology carries less debt relative to equity (5.6% against 150.1%).
| Latest fiscal year | Ascentage Pharma Group InternationalAAPG, 2025 | Kura OncologyKURA, 2025 |
|---|---|---|
| Revenue | $79.9m | $67.5m |
| Revenue growth | -41.4% | 25.2% |
| Net income | −$173m | −$279m |
| Operating margin | — | -449.9% |
| Net margin | -216.5% | -412.9% |
| Return on equity | -153.3% | -94.8% |
| Free cash flow | −$167m | −$70.7m |
| Cash | $171m | $149m |
| Total debt | $284m | $9.7m |
| Debt to equity | 150.1% | 5.6% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $1.3m | — |
| Employees | — | 260 |
| Market value | $1.26bn | $879m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 39 sales |